Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma

BACKGROUND: According to the DESTINY-Breast04 trial, treating patients with breast cancer and low human epidermal growth factor receptor 2 expressions (HER2-low) varies from that of those with no HER2 expression. However, it is interesting to know if HER2-low indicates for anti-HER2 therapy in the g...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, I., Takahari, D., Chin, K., Wakatsuki, T., Takamatsu, M., Yamamoto, N., Ogura, M., Ooki, A., Fukuda, K., Osumi, H., Fukuoka, S., Shinozaki, E., Yamaguchi, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485394/
https://www.ncbi.nlm.nih.gov/pubmed/37348349
http://dx.doi.org/10.1016/j.esmoop.2023.101582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485394/
https://www.ncbi.nlm.nih.gov/pubmed/37348349
http://dx.doi.org/10.1016/j.esmoop.2023.101582

Ejemplares similares